Clinical trial · Observational
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Special Drug Use Investigation (Survey) of Yervoy and Opdivo Combination Therapy in Patients With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
NCT05324436CI-TRIAL-00084878completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mesothelioma, Malignant | Malignant Mesothelioma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort 1
- description
- Participants with unresectable advanced/recurrent malignant pleural mesothelioma (MPM)
Primary outcomes (15)
- measure
- Incidence of Adverse Events (AEs)
- timeFrame
- Up to 6 Months
- measure
- Time to onset of serious adverse events (SAEs)
- timeFrame
- Up to 6 Months
- measure
- Time to onset of AEs
- timeFrame
- Up to 6 Months
- measure
- Time to resolution of AEs
- timeFrame
- Up to 6 Months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Initiated treatment with Yervoy and Opdivo in combination for the first time in accordance with the Japanese package insert Exclusion Criteria: * Received combination therapy with Yervoy and Opdivo for indications other than Malignant Pleural Mesothelioma (MPM). * Received the Yervoy and Opdivo combination for MPM, but for an indication that is outside of the Japanese package insert.
References
Publications (0)
Data not yet available
No reference posted for this study.